Cited by 371Cancer-related Molecular PathwaysHeat shock proteins researchCell death mechanisms and regulation

The DOI matches its Crossref record; 30 of the 37 references it cites were found in a registry or an index.

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Open access

Böttger, Angelika, Böttger, Volker, Sparks, Alison, Liu, Wei-Li, Howard, Stephanie F., Lane, David P.·1997·Current Biology

DOI 10.1016/s0960-9822(06)00374-5

Open this paper in CoChat — free account Open PDF

Abstract

Background The transcriptional activation function of the p53 tumour suppressor protein is induced by DNA damage and results in growth arrest and/or apoptotic responses. A key component of this response is the dramatic rise in p53 protein concentration resulting from an increase in the protein's stability. Very recently, it has been suggested that interaction with the Mdm2 protein may target p53 for rapid degradation. We have designed a gene encoding a small protein that binds tightly to the p53-binding pocket on the Mdm2 protein. We have constructed the gene by cloning a phage display optimised Mdm2-binding peptide into the active-site loop of thioredoxin. Results When introduced into cells containing low levels of wild-type p53, this protein causes a striking accumulation of the endogenous p53 protein, activation of a p53-responsive reporter gene, and cell cycle arrest mimicking the effects seen in these cells after exposure to UV or ionising radiation. Microinjection of a monoclonal antibody to the p53-binding site on Mdm2 achieves a similar effect, establishing its specificity. Conclusions These results demonstrate that the p53 response is constitutively regulated in normal cells by Mdm2 and that disruption of the interaction alone is sufficient to stabilise the p53 protein and activate the p53 response. Our mini protein approach provides a powerful new method to activate p53 without causing DNA damage. More broadly, it establishes a powerful general method for determinin…

Integrity signals

Registry

Crossref · 10.1016/s0960-9822(06)00374-5

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53-mdm-2 autoregulatory feedback loop.
Wu, X., Bayle, J. H., Olson, D., & Levine, A. J. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1126 · Cited by 1,801
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,474
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280

Show all 37 references

Sorted by citations

Items 101–200 of 371

Intrinsically disordered proteins and novel strategies for drug discovery
Uversky, V. N. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.686489 · Cited by 120
Pathologies Associated with the p53 ResponsePreprint
Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 119
Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture.
Freedman, D. A., & Levine, A. J. (1999) · PubMed · Cited by 114
Regulation of p53 Stability and Function in HCT116 Colon Cancer Cells
Kaeser, M. D., Kaeser-Pebernard, S., & Iggo, R. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311732200 · Cited by 113
Targeting Protein–Protein Interactions and Fragment-Based Drug Discovery
Valkov, E., Sharpe, T., Marsh, M., Greive, S., & Hyvönen, M. (2011) · Topics in Current Chemistry · doi:10.1007/128_2011_265 · Cited by 107
MdmX Is a RING Finger Ubiquitin Ligase Capable of Synergistically Enhancing Mdm2 Ubiquitination
Badciong, J. C., & Haas, A. L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208593200 · Cited by 108
Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang, H., Nan, L., Yu, D. S., Agrawal, S., & Zhang, R. (2001) · PubMed · Cited by 106
Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage
Solozobova, V., Rolletschek, A., & Blattner, C. (2009) · BMC Cell Biology · doi:10.1186/1471-2121-10-46 · Cited by 107
Regulation of transcription factors by protein degradation
Desterro, J. M. P., Rodríguez, M. S., & Hay, R. T. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000760 · Cited by 101
Analysis of the degradation function of Mdm2.
Kubbutat, M. H. G., Ludwig, R., Levine, A. J., & Vousden, K. H. (1999) · PubMed · Cited by 102
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 101
MDM2: life without p53
Daujat, S., NEEL, H., & PIETTE, J. (2001) · Trends in Genetics · doi:10.1016/s0168-9525(01)02369-1 · Cited by 97
Transducible Peptide Therapy for Uveal Melanoma and Retinoblastoma
Harbour, J. W. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1341 · Cited by 98
Improving cancer therapy by non-genotoxic activation of p53
Laı́n, S., & Lane, D. P. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00063-7 · Cited by 99
Self-citation
Clostridium difficile Toxin A–Induced Colonocyte Apoptosis Involves p53-Dependent p21(WAF1/CIP1) Induction via p38 Mitogen-Activated Protein Kinase
Kim, H., Kokkotou, E. G., Na, X., Rhee, S. H., Moyer, M. P., Pothoulakis, C., & LaMont, J. T. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.09.011 · Cited by 96
Role for p300 in Stabilization of p53 in the Response to DNA Damage
Yuan, Z.-M., Huang, Y., Ishiko, T., Nakada, S., Utsugisawa, T., Shioya, H., Utsugisawa, Y., Yokoyama, K. K., Weichselbaum, R. R., Shi, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.4.1883 · Cited by 97
Unleashing the power of p53: lessons from mice and men: Figure 1.Preprint
Poyurovsky, M. V., & Prives, C. L. (2006) · Genes & Development · doi:10.1101/gad.1397506 · Cited by 96
c-Abl Regulates p53 Levels under Normal and Stress Conditions by Preventing Its Nuclear Export and Ubiquitination
Vogt Sionov, R., Coen, S., Goldberg, Z., Berger, M., Bercovich, B., Ben-Neriah, Y., Ciechanover, A., & Haupt, Y. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5869-5878.2001 · Cited by 94
mdm2: a bridge over the two tumour suppressors, p53 and Rb
Yap, D., Hsieh, J.-K., Chan, F., & Lü, X. (1999) · Oncogene · doi:10.1038/sj.onc.1202954 · Cited by 93
Inhibition of p53‐dependent transcription by BOX‐I phospho‐peptide mimetics that bind to p300
Dornan, D., & Hupp, T. R. (2001) · EMBO Reports · doi:10.1093/embo-reports/kve025 · Cited by 93
P14ARF promotes accumulation of SUMO-1 conjugated (H)Mdm2
Xirodimas, D. P., Chisholm, J., Desterro, J. M. S., Lane, D. P., & Hay, R. T. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03310-0 · Cited by 94
Self-citation
Hypoxia attenuates the p53 response to cellular damage
Achison, M., & Hupp, T. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206434 · Cited by 93
Involvement of the DNA Repair Protein hHR23 in p53 Degradation
Glockzin, S., Ogi, F.-X., Hengstermann, A., Scheffner, M., & Blattner, C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.8960-8969.2003 · Cited by 93
Contribution of two independent MDM2-binding domains in p14ARF to p53 stabilization
Lohrum, M. A. E., Ashcroft, M. A., Kubbutat, M. H. G., & Vousden, K. H. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00472-3 · Cited by 91
A Nonpeptidic Sulfonamide Inhibits the p53−mdm2 Interaction and Activates p53-Dependent Transcription in mdm2-Overexpressing Cells
Galatin, P. S., & Abraham, D. J. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm034182u · Cited by 90
The p53 network: p53 and its downstream genes
Shu, K., Li, B., & Wu, L. (2006) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2006.11.003 · Cited by 91
Regulation and activation of p53 and its family members
Lohrum, M. A. E., & Vousden, K. H. (1999) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400625 · Cited by 91
Multiple Peptide Conformations Give Rise to Similar Binding Affinities: Molecular Simulations of p53-MDM2
Dastidar, S. G., Lane, D. P., & Verma, C. S. (2008) · Journal of the American Chemical Society · doi:10.1021/ja804289g · Cited by 87
Self-citation
From p63 to p53 across p73
Strano, S., Rossi, M., Fontemaggi, G., Munarriz, E. R., Soddu, S., Sacchi, A., & Blandino, G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02119-6 · Cited by 87
Rapid recruitment of p53 to DNA damage sites directs DNA repair choice and integrity
Wang, Y., Ho, T. L. F., Hariharan, A., Goh, H. C., Wong, Y. L., Verkaik, N. S., Lee, M. Y., Tam, W. L., van Gent, D. C., Venkitaraman, A. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113233119 · Cited by 89
Self-citation
Design and Validation of a Neutral Protein Scaffold for the Presentation of Peptide Aptamers
Woodman, R., Yeh, J. T. ‐., Laurenson, S. X., & Ferrigno, P. K. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.08.001 · Cited by 87
A New Twist in the Feedback Loop: Stress-Activated MDM2 Destabilization is Required for p53 Activation
Stommel, J. M., & Wahl, G. M. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1522 · Cited by 90
Monitoring the Effects of Antagonists on Protein−Protein Interactions with NMR Spectroscopy
D’Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh, M., & Holak, T. A. (2005) · Journal of the American Chemical Society · doi:10.1021/ja052143x · Cited by 88
Miniature Protein Inhibitors of the p53–hDM2 Interaction
Kritzer, J. A., Zutshi, R., Cheah, M. T., Ran, F. A., Webman, R. B., Wongjirad, T. M., & Schepartz, A. (2006) · ChemBioChem · doi:10.1002/cbic.200500324 · Cited by 90
Therapeutic peptides for cancer therapy. Part I – peptide inhibitors of signal transduction cascades
Bidwell, G. L., & Raucher, D. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903143745 · Cited by 85
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 87
p53 as a target for anti-cancer drug development
Bouchet, B. P., de Fromentel, C. C., Puisieux, A., & Galmarini, C. M. (2006) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.10.005 · Cited by 90
A 16-Residue Peptide Fragment of Macrophage Migration Inhibitory Factor, MIF-(50–65), Exhibits Redox Activity and Has MIF-like Biological Functions
Nguyen, M. T., Beck, J., Lue, H., Fünfzig, H., Kleemann, R., Koolwijk, P., Kapurniotu, A., & Bernhagen, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301735200 · Cited by 84
Identification of the Spiro(oxindole-3,3′-thiazolidine)-Based Derivatives as Potential p53 Activity Modulators
Gomez-Monterrey, I. M., Bertamino, A., Porta, A., Carotenuto, A., Musella, S., Aquino, C., Granata, I., Sala, M., Brancaccio, D., Picone, D., et al. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100838z · Cited by 83
Rational Design and Binding Mode Duality of MDM2–p53 Inhibitors
Gonzalez-Lopez de Turiso, F., Sun, D., Rew, Y., Bartberger, M. D., Beck, H. P., Canon, J., Chen, A., Chow, D., Correll, T. L., Huang, X., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400293z · Cited by 82
The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53–HDM2 complex structure
Zhao, J., Wang, M., Chen, J., Luo, A., Wang, X., Wu, M., Yin, D., & Liu, Z. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00084-8 · Cited by 80
Reviving the guardian of the genome: Small molecule activators of p53
Nguyen, D., Liao, W., Zeng, S. X., & Lu, H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.013 · Cited by 84
Inhibition of Transforming Growth Factor-β1–induced Signaling and Epithelial-to-Mesenchymal Transition by the Smad-binding Peptide Aptamer Trx-SARA
Zhao, B. M., & Hoffmann, F. M. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-10-0990 · Cited by 81
Characterization of an E1A-CBP Interaction Defines a Novel Transcriptional Adapter Motif (TRAM) in CBP/p300
O’Connor, M. J., Zimmermann, H., Nielsen, S. J., Bernard, H., & Kouzarides, T. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3574-3581.1999 · Cited by 81
Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53
Li, C., Pazgier, M., Liu, M., Lu, W., & Lu, W. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200904550 · Cited by 81
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms
Wang, H., Yu, D., Agrawal, S., & Zhang, R. (2003) · The Prostate · doi:10.1002/pros.10187 · Cited by 78
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
How to design a drug for the disordered proteins?
Chen, C. Y., & Tou, W. I. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.04.008 · Cited by 78
Ubiquitin and Ubiquitin-Like Modifications of the p53 Family
Watson, I. R., & Irwin, M. S. (2006) · Neoplasia · doi:10.1593/neo.06439 · Cited by 77
Use of a Retroinverso p53 Peptide as an Inhibitor of MDM2
Sakurai, K., Chung, H. S., & Kahne, D. E. (2004) · Journal of the American Chemical Society · doi:10.1021/ja044883w · Cited by 76
Turning a Scorpion Toxin into an Antitumor Miniprotein
Li, C., Liu, M., Monbo, J., Zou, G., Li, C., Yuan, W., Zella, D., Lu, W., & Lu, W. (2008) · Journal of the American Chemical Society · doi:10.1021/ja8042036 · Cited by 75
Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors 2 2Abbreviations: CP, cyclophosphamide; PFT, pifithrin-α or p53 inhibitor; HT, hyperthermia; HS, heat shock; HO, hypoxia; and HIF-1, hypoxia inducible factor.
Komarova, E. A., & Gudkov, A. V. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00733-x · Cited by 75
Ubiquitous Induction of p53 in Tumor Cells by Antisense Inhibition of MDM2 Expression
Chen, L., Lu, W., Agrawal, S., Zhou, W., Zhang, R., & Chen, J. (1999) · Molecular Medicine · doi:10.1007/bf03402136 · Cited by 73
Accumulating Active p53 in the Nucleus by Inhibition of Nuclear Export: A Novel Strategy to Promote the p53 Tumor Suppressor Function
Laı́n, S., Xirodimas, D. P., & Lane, D. P. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4672 · Cited by 72
Self-citation
Cytoplasmically “Sequestered” Wild Type p53 Protein Is Resistant to Mdm2-mediated Degradation
Zaika, A. I., Marchenko, N. D., & Moll, U. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.27474 · Cited by 72
Human papillomavirus E6-induced degradation of E6TP1 is mediated by E6AP ubiquitin ligase.
Gao, Q., Kumar, A., Singh, L., Huibregtse, J. M., Beaudenon, S. L., Srinivasan, S. V., Wazer, D. E., Band, H., & Band, V. (2002) · PubMed · Cited by 69
Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer Agents
Buolamwini, J. K., Addo, J. K., Kamath, S., Patil, S. A., Mason, M., & Ores, M. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332672 · Cited by 69
On the industrial applications of MCRs: molecular diversity in drug discovery and generic drug synthesis
Kalinski, C., Umkehrer, M., Weber, L., Kolb, J., Burdack, C., & Roß, G. (2010) · Molecular Diversity · doi:10.1007/s11030-010-9225-x · Cited by 68
Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site
Tamara, N., Rosal, R. V., Drew, L., Raffo, A. J., Michl, J., Pincus, M. R., Friedman, F. K., Petrylak, D. P., Cassai, N. D., Szmulewicz, J., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206258 · Cited by 68
Dangerous habits of a security guard: the two faces of p53 as a drug target
Gudkov, A. V., & Komarova, E. A. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm052 · Cited by 67
Drug discovery and mutant p53
Maslon, M. M., & Hupp, T. R. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.06.005 · Cited by 68
It’s Getting Complicated—A Fresh Look at p53-MDM2-ARF Triangle in Tumorigenesis and Cancer Therapy
Kung, C.-P., & Weber, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.818744 · Cited by 71
The dual interaction of antimicrobial peptides on bacteria and cancer cells; mechanism of action and therapeutic strategies of nanostructures
Parchebafi, A., Tamanaee, F., Ehteram, H., Ahmad, E., Nikzad, H., & Kashani, H. H. (2022) · Microbial Cell Factories · doi:10.1186/s12934-022-01848-8 · Cited by 65
Wild type p53 reactivation: From lab bench to clinic
Selivanova, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.03.049 · Cited by 68
Determinants of Specificity of MDM2 for the Activation Domains of p53 and p65: Proline27 Disrupts the MDM2-Binding Motif of p53
Zondlo, S. C., Lee, A. E., & Zondlo, N. J. (2006) · Biochemistry · doi:10.1021/bi060309g · Cited by 66
Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present)
Żak, K. M., Pęcak, A., Ryś, B., Władyka, B., Dömling, A. S. S., Weber, L., Holak, T. A., & Dubin, G. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.765405 · Cited by 65
ATM complexes with HDM2 and promotes its rapid phosphorylation in a p53-independent manner in normal and tumor human cells exposed to ionizing radiation
de Toledo, S. M., Azzam, E. I., Dahlberg, W. K., Gooding, T. B., & Little, J. B. (2000) · Oncogene · doi:10.1038/sj.onc.1204020 · Cited by 64
A novel flexible framework with automatic feature correspondence optimization for nonrigid registration in radiotherapy
Osorio, E. M. V., Hoogeman, M. S., Bondar, L., Levendag, P. C., & Heijmen, B. J. M. (2009) · Medical Physics · doi:10.1118/1.3134242 · Cited by 62
Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains
Hay, T., & Meek, D. W. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01850-0 · Cited by 62
The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel Strategies for Prostate Cancer Radiotherapy
Udayakumar, T. S., Shareef, M. M., Diaz, D. A., Ahmed, M. M., & Pollack, A. S. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.05.007 · Cited by 62
Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells
Kim, H. J., Vosseler, C. A., Weber, P. C., & Erl, W. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20351 · Cited by 61
Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity
Leonard, K. A., Marugán, J., Raboisson, P., Calvo, R. R., Gushue, J. M., Koblish, H. K., Lattanze, J., Zhao, S., Cummings, M. D., Player, M. R., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.04.009 · Cited by 61
Binding of p53-derived Ligands to MDM2 Induces a Variety of Long Range Conformational Changes
Schön, O., Friedler, A., Freund, S. M. V., & Fersht, A. R. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.11.051 · Cited by 58
p14 Arf Promotes Small Ubiquitin-like Modifier Conjugation of Werners Helicase
Woods, Y. L., Xirodimas, D. P., Prescott, A. R., Sparks, A., Lane, D. P., & Saville, M. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405414200 · Cited by 59
Self-citation
Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways
Blaydes, J. P., Craig, A. L., Wallace, M., Ball, H. M.-L., Traynor, N. J., Gibbs, N. K., & Hupp, T. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203773 · Cited by 60
Recent Small-Molecule Inhibitors of the p53–MDM2 Protein–Protein Interaction
Beloglazkina, A. A., Zyk, N. V., Majouga, A. G., & Beloglazkina, E. K. (2020) · Molecules · doi:10.3390/molecules25051211 · Cited by 59
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop
Arriola, E. L., Lopez, A. R., & Chresta, C. M. (1999) · Oncogene · doi:10.1038/sj.onc.1202391 · Cited by 58
Mdm2: A Regulator of Cell Growth and Death
Alarcon-Vargas, D., Takahashi, S., & Ronai, Z. A. (2003) · Advances in cancer research · doi:10.1016/s0065-230x(03)01001-7 · Cited by 57
MEK-ERK Signaling Controls Hdm2 Oncoprotein Expression by Regulating hdm2 mRNA Export to the Cytoplasm
Phelps, M., Phillips, A., Darley, M., & Blaydes, J. P. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412334200 · Cited by 57
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57
Selective inhibition of TGF-β responsive genes by Smad-interacting peptide aptamers from FoxH1, Lef1 and CBP
Cui, Q., Lim, S. K., Zhao, B. M., & Hoffmann, F. M. (2005) · Oncogene · doi:10.1038/sj.onc.1208556 · Cited by 56
Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation
Conforti, G., Nardò, T., D’Incalci, M., & Stefanini, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203583 · Cited by 55
Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction
Rothweiler, U., Czarna, A., Krajewski, M., Ciombor, J., Kalinski, C., Khazak, V., Roß, G., Skobeleva, N., Weber, L., & Holak, T. A. (2008) · ChemMedChem · doi:10.1002/cmdc.200800025 · Cited by 55
Therapeutic anti-cancer targets upstream of the proteasome
Nalepa, G. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00083-5 · Cited by 53
Pilot screening programme for small molecule activators of p53
Berkson, R., Hollick, J. J., Westwood, N. J., Woods, J. A., Lane, D. P., & Laı́n, S. (2005) · International Journal of Cancer · doi:10.1002/ijc.20968 · Cited by 52
Self-citation
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 51
Cell‐Permeable β‐Peptide Inhibitors of p53/hDM2 Complexation
Harker, E. A., & Schepartz, A. (2009) · ChemBioChem · doi:10.1002/cbic.200900049 · Cited by 51
p53-Oriented cancer therapies: Current progress
Gallagher, W. M., & Brown, R. E. (1999) · Annals of Oncology · doi:10.1023/a:1008368500557 · Cited by 51
Anti-Tumor Efficacy of a Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotide in Human Colon Cancer Models: p53-Dependent and p53-Independent Mechanisms
Wang, H., Nan, L., Yu, D. S., Lindsey, J. R., Agrawal, S., & Zhang, R. (2002) · Molecular Medicine · doi:10.1007/bf03402011 · Cited by 50
Combinatorial protein reagents to manipulate protein function
Colas, P. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00051-4 · Cited by 50
Recent Advances in Validating MDM2 as a Cancer Target
Rayburn, E. R., Ezell, S. J., & Zhang, R. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009789124628 · Cited by 50
Using a β‐Hairpin To Mimic an α‐Helix: Cyclic Peptidomimetic Inhibitors of the p53–HDM2 Protein–Protein Interaction
Fasan, R., Dias, R. L. A., Moehle, K., Zerbe, O., Vrijbloed, J. W., Obrecht, D., & Robinson, J. A. (2004) · Angewandte Chemie · doi:10.1002/ange.200353242 · Cited by 48
Development of a Binding Assay for p53/HDM2 by Using Homogeneous Time-Resolved Fluorescence
Kane, S. A., Fleener, C., Zhang, Y., Davis, L. J., Musselman, A., & Huang, P. S. (2000) · Analytical Biochemistry · doi:10.1006/abio.1999.4413 · Cited by 47
Monomeric Recombinant Peptide Aptamers Are Required for Efficient Intracellular Uptake and Target Inhibition
Borghouts, C., Kunz, C., Delis, N., & Groner, B. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0245 · Cited by 46
Small molecule activators of the p53 response
Ladds, M. J. G. W., & Laín, S. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz006 · Cited by 46
Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53
Lin, J.-Y., Ohshima, T., & Shimotohno, K. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.059 · Cited by 47
Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen
Wu, H., Jung, M.-Y., Chiu, C., Chao, T.-T., Lai, S.-C., Jan, J., & Shaio, M. (2003) · Journal of General Virology · doi:10.1099/vir.0.19228-0 · Cited by 46
Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells
Hjerrild, M., Milne, D., Dumaz, N., Hay, T., Issinger, O., & Meek, D. W. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3550347 · Cited by 45
Regulated nuclear localization of stress-responsive factors: how the nuclear trafficking of protein kinases and transcription factors contributes to cell survival
Ferrigno, P. K., & Silver, P. A. (1999) · Oncogene · doi:10.1038/sj.onc.1203132 · Cited by 43
p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy
Ganly, I., Soutar, D. S., Brown, R. E., & Kaye, S. B. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0932 · Cited by 42

Authors: Böttger, A., Böttger, V., Sparks, A., Liu, W.-L., Howard, S. F., & Lane, D. P.
Affiliations: University of Dundee (GB)
Corresponding author: Lane, David P.
ORCID: Böttger, Angelika
Lane, David P.
Venue: Current Biology
Publisher: Elsevier BV
Published: 1997-11
Volume: 7
Issue: 11
Pages: 860-869
ISSN: 0960-9822 (ISSN-L)
DOI: 10.1016/s0960-9822(06)00374-5
OpenAlex: W2041568308
Cited by: 363
References: 37
Citations by year: 2024: 1 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 7 · 2016: 2 · 2015: 4 · 2014: 12 · 2013: 6 · 2012: 12
FWCI: 11.86
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 5737 d)
Locations: Current Biology (publishedVersion)
PubMed (publishedVersion)
Funders: European Commission
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Keywords: p53, MDM2, p53-MDM2 interaction, protein-protein interaction disruption, thioredoxin, p53 stabilization, transcriptional activation, cell cycle arrest, phage display peptides, DNA damage response, tumour suppressor
MeSH terms: Amino Acid Sequence, Animals, Binding, Competitive, Cell Cycle, Cell Line, Humans, Male, Molecular Sequence Data, Nuclear Proteins, Prostate, Protein Binding, Proto-Oncogene Proteins, Recombinant Fusion Proteins, Thioredoxins, Transfection, Tumor Cells, Cultured, Protein Engineering, Transcriptional Activation, Tumor Suppressor Protein p53, Mice, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks